Clinical trials: Palmar Hyperhidrosis
Hyperhidrosis
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
Umeclidinium (UMEC) is a potent pan-active long-acting muscarinic antagonist (LAMA). It is anticipated that topical administration of UMEC will block stimulation of muscarinic receptors, thereby reducing the overproduction of…
- Trial name
- NCT02673619
- Testing
- Umeclidinium, Vehicle
- Where
- 6 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Stiefel, a GSK Company
Hyperhidrosis, Hyperhidrosis Palmaris et Plantaris
Management of Palmar Hyperhidrosis With Hydrogel-based Iontophoresis
This study will evaluate the use of hydrogel electrode pads (rather than tap water baths) to deliver iontophoresis treatment using a traditional iontophoresis device.
- Trial name
- NCT02854540
- Testing
- Hydrogel electrode-based iontophoresis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Palmar Hyperhidrosis
A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
The objective of this study is to assess the efficacy and safety of glycopyrronium cloth, 2.4% when used to treat palmar hyperhidrosis.
- Trial name
- NCT03880266
- Testing
- Glycopyrronium cloth, 2.4%, Vehicle
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis
A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis
To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.
- Trial name
- NCT02682238
- Testing
- BBI-4000, 15%, Vehicle gel
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Botanix Pharmaceuticals
Primary Focal Hyperhidrosis of the Hands
BTX-A Treatment for Palmar Hyperhidrosis
Primary focal hyperhidrosis (excessive sweating) is a debilitating condition affecting approximately 3% of the population in the United States.
- Trial name
- NCT01262339
- Testing
- BTX-A
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison